Clinical trials: Diarrhea Predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome
The Effects of Bifidobacterium Breve Bif195 for Diarrhea-predominant Irritable Bowel Syndrome
The purpose of this study is to investigate if the probiotic Bifidobacterium breve Bif195 (Bif195) will result in improvement in clinical outcome in patients with diarrhea-predominant irritable bowel syndrome (IBS).
- Trial name
- NCT04808271
- Testing
- Bifidobacterium breve Bif195
- Where
- 2 sites in Denmark
- Volunteers
- 61 people
- Sponsor
- Hvidovre University Hospital
IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
This is a double-blind, randomized (group assignment by chance), placebo-controlled, multicenter trial which will be conducted over a 13.5-months period The main objective of the research is to demonstrate the efficacy of…
- Conditions
- IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant), IBS, Mixed Symptoms
- Trial name
- BoWell Sb252 (NCT07168434)
- Testing
- Saccharomyces Boulardii 250 MG
- Where
- 10 sites in Portugal, Spain
- Volunteers
- 406 people
- Sponsor
- Biocodex
Irritable Bowel Syndrome With Diarrhea (IBS-D)
A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
To evaluate the safety and tolerability, treatment effect on abdominal pain, and dose response of MD-7246 administered orally to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
- Trial name
- NCT03931785
- Testing
- MD-7246
- Where
- 80 sites in United States
- Volunteers
- 515 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome
Effect of a Probiotic, Lactobacillus FARCIMINIS, in Diarrhea Predominant IBS Patients
Probiotics may improve symptoms in IBS patients. The aim of this study is to test the efficacy of Lactobacillus FARCIMINIS in diarrhea predominant IBS patients according to Rome III criteria.
- Trial name
- NCT00561535
- Testing
- Lactobacillus FARCIMINIS
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diarrhea-predominant Irritable Bowel Syndrome
Effects of Vitamin D on Gut Microbiota, Intestinal Barrier in IBS-D Patients
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disease. Evidence suggests that the concentration of serum VD is decreased in IBS patients, particularly in IBS-D.
- Trial name
- NCT05593367
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Irritable Bowel Syndrome With Diarrhea
To Study the Efficacy and Safety of L. Plantarum UALp-05TM in Diarrhea- Predominant-irritable Bowel Syndrome
Several probiotic strains have shown beneficial outcomes in IBS patients, particularly among the Lactobacillus and Bifidobacterium genera, Lactobacillus plantarum (recently reclassified as Lactiplantibacillus plantarum) is a…
- Trial name
- NCT04950296
- Testing
- Group I: L. plantarum UALp-05TM,, Group II: L. plantarum UALp-05TM,, Microcrystalline cellulose
- Where
- 12 sites in India
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea (IBS-D)
Efficacy of Repeated Transcranial Magnetic Stimulation Combined With a Live Probiotic Tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
To evaluate the overall efficacy of repeated Transcranial Magnetic Stimulation(rTMS) combined with a Live Probiotic tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live) in…
- Conditions
- Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea (IBS-D), Repetitive Transcranial Magnetic Stimulation (rTMS), Probiotic
- Trial name
- NCT06960369
- Testing
- rTMS combined with Live Probiotic tablet
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Soochow University
Irritable Bowel Syndrome
Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome
In patients with IBS, will supplementation with a probiotic demonstrate symptomatic efficacy and will the probiotic influence gut microflora and thus improve clinical outcomes, as compared to no intervention.
- Trial name
- NCT01886781
- Testing
- Lactobacillus plantarum 299v, Run in period, Wash - out period
- Where
- South Africa
- Volunteers
- 81 people
- Sponsor
- University of Stellenbosch
Diarrhea-predominant Irritable Boewl Syndrome
Efficacy and Safety of Modified Gegen Qinlian Decoction for Diarrhea-predominant Irritable Boewl Syndrome
Diarrhea-predominant irritable boewl syndrome(IBS-D) seriously affect the quality of life in patients. Clinically, it is effective to apply therapeutic method of clearing heat and promoting diuresis to the common syndrome of…
- Trial name
- NCT04312477
- Testing
- Modified Gegen Qinlian Decoction
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
Irritable Bowel Syndrome
Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a common disease and the pathogenesis of this disease includes central and peripheral mechanisms.
- Trial name
- NCT02565654
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Irritable Bowel Syndrome
SBI in Children With d-IBS
IBS is the most common diagnosis in new patients in our pediatric gastroenterology clinic, accounting for 36 % of all new patients.
- Trial name
- NCT02609529
- Testing
- Medical Food
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Irritable Bowel Syndrome
LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
An observational study to evaluate LOTRONEX® in women with severe IBS-D in the current clinical practice setting.
- Trial name
- RELIANCE (NCT01257477)
- Where
- 67 sites in United States
- Volunteers
- 400 people
- Sponsor
- Prometheus Laboratories
Diarrhea-predominant Irritable Bowel Syndrome
Clinical Efficacy and Safety of Jingfang Granules in Treating Diarrhea-Predominant Irritable Bowel Syndrome With Cold-Dampness Disturbing Spleen Syndrome
This prospective, open-label, randomized controlled clinical trial aims to evaluate the clinical efficacy and safety of Jingfang Granules in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) with…
- Trial name
- NCT07688161
- Testing
- Trimebutine Maleate Tablets, Jingfang Granules
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Irritable Bowel Syndrome
Study to Determine Efficacy of Probiotics in Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is the most common functional GI disorder in which abdominal pain and/or discomfort is associated with changes in bowel habit, and with features of disordered defecation.
- Trial name
- NCT02545413
- Testing
- Probiotic VSL#3
- Where
- India
- Sponsor
- Next Gen Pharma India Pvt. Ltd.
IBS-D (Diarrhea-predominant)
Effect of Ramosetron in Patients With Diarrhea Predominant Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) tends to be a lifelong disorder and it is often frustrating to both patients and physicians. This study aim of improving symptom control, reducing healthcare burden and upgrading the quality of life…
- Trial name
- NCT07574320
- Testing
- Ramosetron 2.5 microgram
- Volunteers
- 76 people
- Sponsor
- Md. Aminul Islam
Irritable Bowel Syndrome
8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS
In this study, female patients with IBS-d will be treated for 8 weeks to assess the safety and effectiveness of DDP225 on GI transit and in reducing IBS symptoms.
- Trial name
- NCT00230581
- Testing
- DDP225
- Where
- 16 sites in United States, Canada
- Volunteers
- 88 people
- Sponsor
- Dynogen Pharmaceuticals
Irritable Bowel Syndrome
A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome
The objective of this study is to evaluate the safety and efficacy of LX1033 over a range of dose levels in subjects with diarrhea-predominant Irritable Bowel Syndrome (IBS).
- Trial name
- NCT01494233
- Testing
- 250 mg LX1033 tablets
- Where
- 81 sites in United States
- Volunteers
- 373 people
- Sponsor
- Lexicon Pharmaceuticals
Diarrhea-predominant Irritable Bowel Syndrome
Special Drug Use Surveillance of Irribow in Female Patients
The purpose of the survey is to evaluate the safety and efficacy of Irribow and Irribow OD Tablets in post-marketing medical practice and to examine the status of treatment compliance.
- Trial name
- NCT02612649
- Testing
- Ramosetron
- Where
- 34 sites in Japan
- Volunteers
- 793 people
- Sponsor
- Astellas Pharma Inc
Irritable Colon
Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)
This study is an exploratory study aiming (i) to obtain clinical experience of GR68755 in Japanese subjects with severe d-IBS to explore the feasibility of the next phase study and (ii) to obtain reference data for endpoints and…
- Trial name
- NCT01855711
- Testing
- GR68755 (Alosetron hydrochloride) 1 mg tablet
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Gulf War Digestive Health Study
The purposes of this study are to estimate the burden of disease due to chronic gastrointestinal illness in PG veterans, to evaluate whether Small Bowel Bacterial Overgrowth (SBBO) is associated with chronic diarrhea in PG…
- Trial name
- NCT00680836
- Testing
- Rifaximin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- US Department of Veterans Affairs